TrialRheumatology (Oxford, England)2021

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.

Nicolino Ruperto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.